stem cell therapy in Covid-19

Phase 2

Recruiting

• Conditions: Covid-19 disease.; Severe Acute Respiratory Syndrome coronavirus; RA01.0

• Registration Number: IRCT20160809029275N1
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 15 June 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Covid-19 patient with acute respirstory infectious symptoms and severe lung involvement
Pulmonary compliance more than 40
Age category 18-70 years
PI02/FIo2 between 100 - 300

Exclusion Criteria

Covid-19 patient with Sepsis
Pregnancy
The presence of malignancy or other underlying diseases
Patient with age conditions outside the range of 18-70 years

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Respiratory symptoms and pulmonary function in patients. Timepoint: In onset of study and days 2, 7 and 14 after the second injection. Method of measurement: Using CT scan image , physical examination , Oxygen saturation Percentage.;Evaluation of IFN-?,IL4,TGF-ß,IL1-ß , IL-6 and TNF-a cytokine levels in patients blood. Timepoint: In onset of study and days 2, 7 and 14 after the second injection. Method of measurement: Using Elisa kits.;Cell markers and populations. Timepoint: In onset of study and days 2, 7 and 14 after the second injection. Method of measurement: Using Flow cytometery technique.